Cocrystal Pharma to Present at the H.C. Wainwright Global Life Sciences Virtual Conference [UPDATED]
March 02 2021 - 11:28AM
Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the
“Company”), a clinical-stage biotechnology company discovering and
developing novel antiviral therapeutics that target the replication
machinery of influenza viruses, the SARS-CoV-2 virus, hepatitis C
viruses and noroviruses, announces that management will present a
company overview and hold virtual investor meetings at the H.C.
Wainwright Global Life Sciences Virtual Conference being held March
9-10, 2021.
The Cocrystal Pharma webcast presentation can be
accessed by registering for the H.C. Wainwright Global Life
Sciences Virtual Conference here. The webcast will be available on
the H.C. Wainwright Conference Portal beginning March 9, 2021 at
7:00 a.m. Eastern time through March 10, 2021 at 9:00 p.m. Eastern
time. The Company’s corporate presentation can be accessed from the
Investor Relations section of the Company website here.
About Cocrystal Pharma,
Inc.Cocrystal Pharma, Inc. is a clinical-stage
biotechnology company discovering and developing novel antiviral
therapeutics that target the replication process of influenza
viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses
and noroviruses. Cocrystal employs unique structure-based
technologies and Nobel Prize-winning expertise to create first- and
best-in-class antiviral drugs. For further information about
Cocrystal, please visit www.cocrystalpharma.com.
Investor Contact:LHA Investor RelationsJody
Cain310-691-7100jcain@lhai.com
Cocrystal Pharma (NASDAQ:COCP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cocrystal Pharma (NASDAQ:COCP)
Historical Stock Chart
From Sep 2023 to Sep 2024